Ireland - English - HPRA (Health Products Regulatory Authority)

nordisk gentofte a/s - 12 international unit

Ireland - English - HPRA (Health Products Regulatory Authority)

nordisk gentofte a/s - 10 millilitre

Ireland - English - HPRA (Health Products Regulatory Authority)

nordisk gentofte a/s - 10 millilitre

Ireland - English - HPRA (Health Products Regulatory Authority)

nordisk gentofte a/s -

Ireland - English - HPRA (Health Products Regulatory Authority)

nordisk gentofte a/s - 10 millilitre

Ireland - English - HPRA (Health Products Regulatory Authority)

nordisk gentofte a/s - 10 millilitre

Malta - English - Medicines Authority

pharmamentum jægersborg alle 164, 2860 gentofte, denmark - iloprost - concentrate for solution for infusion - iloprost 100 µg/ml - antithrombotic agents

European Union - English - EMA (European Medicines Agency)

abbott laboratories ltd. - adalimumab - spondylitis, ankylosing; arthritis, rheumatoid; arthritis, psoriatic; crohn disease - immunosuppressants - rheumatoid arthritistrudexa in combination with methotrexate, is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.trudexa can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.trudexa has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.psoriatic arthritistrudexa is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.ankylosing spondylitistrudexa is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.crohn's diseasetrudexa is indicated for treatment of severe, active crohn's disease, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. for induction treatment, trudexa should be given in combination with cortiocosteroids. trudexa can be given as monotherapy in case of intolerance to corticosteroids or when continued treatment with corticosteroids is inappropriate (see section 4.2).

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع خوري - khoury drug store - glucagon 1 mg - 1 mg

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع خوري - khoury drug store - somatropin 10 mg/1.5ml - 10 mg/1.5ml